A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung Cancer

New England Journal of Medicine

Volumn 330, Issue 3, 1994, Pages 153-158

  Rosell, Rafael ^b   Gomez Codina, Jose ^c   Camps, Carlos ^d   Maestre, Jose ^a   Padille, Jose ^c   Canto, Antonio ^d   Mate, Jose Luis ^b   li, Shanrong ^b   Roig, Jorge ^b   Olazabal, Angel ^b   Canela, Mercedes ^b   Ariza, Aurelio ^a   Skacel, Zdenek ^b   Morera Prat, Jose ^b   Abad, Albert ^b  

^a Hospital de Badalona Germans Trias i Pujol ^*

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d Hospital General Valencia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; DNA; IFOSFAMIDE; LORAZEPAM; MESNA; METOCLOPRAMIDE; MITOMYCIN;

ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; ONCOGENE RAS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POINT MUTATION; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0027957929     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199401203300301     Document Type: Article

References (35)

1. Martini N, Flehinger BJ The role of surgery in N2 lung cancer. Surg Clin North Am 1987; 67: 1037-1049
2. Bains MS Surgical treatment of lung cancer. Chest 1991; 100: 826-837
3. Watanabe Y, Shimizu J, Oda M, Aggressive surgical intervention in N2 non-small cell cancer of the lung. Ann Thorac Surg 1991; 51: 253-261
4. Naruke T, Goya T, Tsuchiya R, Suemasu K The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastasis. Ann Thorac Surg 1988; 46: 603-610
5. Mountain CF Expanded possibilities for surgical treatment of lung cancer: survival in stage IIIA disease. Chest 1990; 97: 1045-1051
6. Murren JR, Buzaid AC, Hait WN Critical analysis of neoadjuvant therapy for stage IIIa non-small cell lung cancer. Am Rev Respir Dis 1991; 143: 889-894 [Erratum, Rev Respir Dis 1991;143:1473.]
7. Skarin A, Jochelson M, Sheldon T, Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients. J Surg Oncol 1989; 40: 266-274
8. Faber LP, Kittle CF, Warren WH, Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg 1989; 47: 669-677
9. Martini N, Kris MG, Gralla RJ, The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal lymph node metastases (N2 M0). Ann Thorac Surg 1988; 45: 370-379
10. Martini N, Kris MG, Flehinger BJ, Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993; 55: 1365-1374
11. Burkes RL, Ginsberg RJ, Shepherd FA, Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial. J Clin Oncol 1992; 10: 580-586
12. Weiden PL, Piantadosi S Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small-cell lung cancer: a phase II study of the Lung Cancer Study Group. J Natl Cancer Inst 1991; 83: 266-273
13. Strauss GM, Herndon JE, Sherman DD, Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992; 10: 1237-1244
14. Dautzenberg B, Benichou J, Allard P, Failure of the perioperative PCV neoadjuvant polychemotherapy in resectable bronchogenic non-small cell carcinoma: results from a randomized phase II trial. Cancer 1990; 65: 2435-2441
15. Fossella FV, Ryan B, Dhingra H, Interim report of a prospective randomized trial of neoadjuvant chemotherapy plus surgery vs surgery alone for IIIA non-small cell lung cancer. Proc Am Soc Clin Oncol 1991; 10: 240-240 abstract.
16. Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 1992;53:992-8
17. Cullen MH, Joshi R, Chetiyawardana AD, Woodroffe CM Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer 1988; 58: 359-361
18. Mountain CF A new international staging system for lung cancer. Chest 1986; 89: Suppl 4: 225S-233S
19. Loddenkemper R, Gabler A, Gobel D Criteria of functional operability in patients with bronchial carcinoma: preoperative assessment of risk and prediction of postoperative function. Thorac Cardiovasc Surg 1983; 31: 334-337
20. Cottrell JJ, Ferson PF Preoperative assessment of the thoracic surgical patient. Clin Chest Med 1992; 13: 47-53
21. Ratto GB, Frola C, Cantoni S, Motta G Improving clinical efficacy of computed tomographic scan in the preoperative assessment of patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 1990; 99: 416-425
22. Deslauriers J, Brisson J, Cartier R, Carcinoma of the lung: evaluation of satellite nodules as a factor influencing prognosis after resection. J Thorac Cardiovasc Surg 1989; 97: 504-512
23. Rosell R, Moreno I, Maestre J, Cyclophosphamide and ifosfamide combination as neoadjuvant chemotherapy for locally advanced nonsmall-cell lung cancer: a meta-analytic review. J Surg Oncol 1990; 45: 124-130
24. Slebos RJC, Boerrigter L, Evers SG, Wisman P, Mooi WJ, Rodenhuis S A rapid and simple procedure for the routine detection of ras point mutations in formalin-fixed, paraffin-embedded tissues. Diagn Mol Pathol 1992; 1: 136-141
25. Hiddemann W, Schumann J, Andreeff M, Convention on nomenclature for DNA cytometry. Cytometry 1984; 5: 445-446
26. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982;38:29-41.
27. Dixon WJ, ed. BMDP statistical software. Berkeley: University of California Press, 1983:555-94.
28. Gomez-Codina J, Rosell R, Camps C, Effective neoadjuvant chemotherapy (CT) for stage IIIA non-small-cell lung cancer (NSCLC) -- a randomized trial of preoperative MIC CT in comparison with immediate surgery. Eur J Cancer 1991; 27: Suppl 2: S167-S167 abstract.
29. Rosell R, Gomez-Codina J, Camps C, Favourable outcome and aneuploidy reversion following neoadjuvant chemotherapy (CT) in stage IIIA non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1992; 11: 287-287 abstract.
30. Cybulsky IJ, Lanza LA, Ryan MB, Putnam JB Jr, McMurtrey MM, Roth JA Prognostic significance of computed tomography in resected N2 lung cancer. Ann Thorac Surg 1992; 54: 533-537
31. Martini N, Burt ME, Bains MS, McCormack PM, Rusch VW, Ginsberg RJ Survival after resection of stage II non-small cell lung cancer. Ann Thorac Surg 1992; 54: 460-466
32. Slebos RJC, Kibbelaar RE, Dalesio O, K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323: 561-565
33. Mitsudomi T, Steinberg SM, Oie HK, ras Gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991; 51: 4999-5002
34. Rosell R, Li S, Skacel Z, Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 1993; 8: 2407-2412
35. Yu JM, Zhang H, Wang SQ, DNA ploidy analysis of effectiveness of radiation therapy for cervical carcinoma. Cancer 1991; 68: 76-78